Nidlegy is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia. Both companies jointly made the following announcements:
– 23 October 2023 – Phase III PIVOTAL trial met the primary endpoint
– 31 May 2024 – Primary results of PIVOTAL presented at ASCO
– 04 June 2024 – MAA submission to EMA
The data of the Phase III Nidlegy trial are expected to be published in a peer-reviewed scientific journal in 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 04 2024 | 3:04 PM IST
The European Commission and Switzerland completed negotiations Friday on a broad package of agreements to deepen and expand the EU-Switzerland relationship.“T
Stay informed with free updatesSimply sign up to the EU business regulation myFT Digest -- delivered directly to your inbox.Qatar has threatened to stop vital g
6.00pm 20th December 2024 - Sponsorship & Events - This story was updated on Saturday, December 21st, 2024 The Ladies European
VMPLNew Delhi [India], December 20: The European medical devices market, projected to surpass EUR230 billion by 2030, is driven by an a